0.2581

20.31% -0.0658

After Hours: .26 0.0019 +0.74%

Adaptimmune Therapeutics Plc Adr (ADAP)

Overview News Price History Option Chain Financials Discussions Forecast

Adaptimmune Therapeutics Plc Adr stock is traded at $0.2581, with a volume of 2.01M. It is down -20.31% in the last 24 hours and down -46.67% over the past month. Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.

Previous Close:

$0.3239

Open:

$0.315

24h Volume:

2.01M

Relative Volume:

1.16

Market Cap:

$66.39M

Revenue:

$175.04M

Net Income/Loss:

$-44.52M

P/E Ratio:

-1.4339

EPS:

-0.18

Net Cash Flow:

$-56.05M

1W Performance:

+25.29%

1M Performance:

-46.67%

6M Performance:

-72.86%

1Y Performance:

-80.88%

1-Day Range:

$0.25

$0.32

1-Week Range:

$0.1951

$0.3301

52-Week Range:

$0.1951

$1.48

Adaptimmune Therapeutics Plc Adr Stock (ADAP) Company Profile

Name

Adaptimmune Therapeutics Plc Adr

Sector

Healthcare (1171)

Industry

Biotechnology (673)

Phone

44 1235 430000

Address

60 JUBILEE AVENUE, ABINGDON, OXFORDSHIRE

Employee

506

Twitter

@Adaptimmune

Next Earnings Date

2025-03-21

Latest SEC Filings

ADAP's Discussions on Twitter

Compare ADAP with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ADAP Adaptimmune Therapeutics Plc Adr	0.2581	66.39M	175.04M	-44.52M	-56.05M	-0.18
VRTX Vertex Pharmaceuticals Inc	474.62	121.88B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	573.45	62.69B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	555.11	33.86B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	235.74	30.51B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	238.51	25.69B	3.81B	-644.79M	-669.77M	-6.24

Adaptimmune Therapeutics Plc Adr Stock (ADAP) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-30-24	Initiated	H.C. Wainwright	Buy
May-30-24	Initiated	Scotiabank	Sector Outperform
Mar-24-23	Initiated	Bryan Garnier	Buy
Jan-03-23	Upgrade	Guggenheim	Neutral → Buy
Nov-09-22	Upgrade	Mizuho	Neutral → Buy
May-28-21	Initiated	Barclays	Underweight
Apr-22-20	Initiated	Mizuho	Neutral
Aug-02-19	Downgrade	Guggenheim	Buy → Neutral
May-31-19	Initiated	ROTH Capital	Buy
May-30-19	Resumed	Citigroup	Buy
May-07-19	Downgrade	SVB Leerink	Outperform → Mkt Perform
Mar-17-17	Initiated	Wells Fargo	Market Perform
Oct-24-16	Downgrade	BofA/Merrill	Neutral → Underperform
Sep-30-16	Initiated	Raymond James	Outperform
Feb-25-16	Initiated	Citigroup	Buy
Jun-01-15	Initiated	BofA/Merrill	Neutral
Jun-01-15	Initiated	Guggenheim	Buy
Jun-01-15	Initiated	Leerink Partners	Outperform

View All

Adaptimmune Therapeutics Plc Adr Stock (ADAP) Latest News

Apr 02, 2025

Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) Today’s Hot Stock - stocksregister.com

Apr 02, 2025

Apr 01, 2025

H.C. Wainwright cuts Adaptimmune stock target to $3, maintains Buy By Investing.com - Investing.com South Africa

Apr 01, 2025

H.C. Wainwright cuts Adaptimmune stock target to $3, maintains Buy - Investing.com India

Apr 01, 2025

Mar 26, 2025

Guggenheim cuts Adaptimmune target to $1.75, maintains Buy By Investing.com - Investing.com South Africa

Mar 26, 2025

Guggenheim cuts Adaptimmune target to $1.75, maintains Buy - Investing.com India

Mar 26, 2025

Mar 24, 2025

Adaptimmune Therapeutics Amends Loan Agreement - Investing.com India

Mar 24, 2025

Mar 21, 2025

Scotiabank cuts Adaptimmune price target to $1.40, keeps rating By Investing.com - Investing.com South Africa

Mar 21, 2025

Scotiabank cuts Adaptimmune price target to $1.40, keeps rating - Investing.com

Mar 21, 2025

Mar 20, 2025

Mizuho maintains Outperform on Adaptimmune, price target $1.50 By Investing.com - Investing.com South Africa

Mar 20, 2025

Mizuho maintains Outperform on Adaptimmune, price target $1.50 - Investing.com

Mar 20, 2025

Earnings call transcript: Adaptimmune Q4 2024 targets $25M sales in 2025 - Investing.com

Mar 20, 2025

Mar 06, 2025

Adaptimmune Therapeutics PLC Sponsored ADR to Host Earnings Call - ACCESS Newswire

Mar 06, 2025

Feb 25, 2025

LAG-3 Immunotherapies Market Set for Rapid Growth in the Coming 10 Years Across the 7MM as Next-Generation Therapies Advance | DelveInsight - GlobeNewswire Inc.

Feb 25, 2025

Analysts Recommend Holding Your Position In Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) - Stocks Register

Feb 25, 2025

Feb 19, 2025

Investing in Adaptimmune Therapeutics Plc ADR (ADAP) Is Getting More Attractive - Knox Daily

Feb 19, 2025

Feb 12, 2025

Potential Price Increase for Coterra Energy Inc (CTRA) After Recent Insider Activity - Knox Daily

Feb 12, 2025

Taking a Closer Look At Dollar Tree Inc (DLTR) Following Its Recent Trade - Knox Daily

Feb 12, 2025

A Guide To The Risks Of Investing In Agilon Health Inc (AGL) - Knox Daily

Feb 12, 2025

Feb 11, 2025

Daily Progress: Quanterix Corp (QTRX) Drop -3.57, Closing at 7.83 - The Dwinnex

Feb 11, 2025

Feb 08, 2025

Following A 4.11% Weekly Incline, Is It Still A Buy For Amylyx Pharmaceuticals Inc (NASDAQ: AMLX)? - Marketing Sentinel

Feb 08, 2025

Should Outset Medical Inc (NASDAQ: OM) Rally After -544.44% Drop From High? - Marketing Sentinel

Feb 08, 2025

Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) Stock Falling -5.24% Over A Month – Any Room For Its Value To Rise? – Marketing Sentinel - Marketing Sentinel

Feb 08, 2025

BioVie Inc (NASDAQ: BIVI): How Can A Stock Be Down -4.00% Year To Date, But Still Loser - Marketing Sentinel

Feb 08, 2025

Feb 07, 2025